Flupirtine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Flupirtine: From Chronic Pain to Osteoarthritis
One-Sentence Summary
Flupirtine is a centrally-acting non-opioid analgesic historically used for chronic musculoskeletal pain, including pain associated with arthrosis and arthritis. The TxGNN model predicts it may be effective for Osteoarthritis, but this direction is currently supported only by 0 clinical trials and 4 publications — none of which directly studied flupirtine in osteoarthritis patients.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic pain (arthrosis/arthritis pain) — inferred from cited literature; no formal Taiwan label data available |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.64% |
| Evidence Level | L4 |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal DrugBank/TFDA mechanism-of-action documentation for flupirtine is currently a data gap in this evidence pack. However, the literature and mechanistic rationale captured alongside the predictions consistently describe flupirtine as a Kv7/KCNQ potassium channel opener. This action hyperpolarizes sensory neurons and produces analgesia through indirect NMDA-receptor antagonism and GABA-A potentiation — a central pain-modulating mechanism, not an anti-inflammatory or disease-modifying one.
This mechanism is consistent with flupirtine’s historical use: a 12-month open-label study (PMID 2451818) treated patients with chronic pain “in particular arthrosis and arthritis,” indicating the drug’s original niche already overlapped with degenerative joint pain. Osteoarthritis and arthrosis/arthritis pain are clinically adjacent — both are characterized by chronic nociceptive and neuropathic joint pain — so extending a centrally-acting analgesic from one to the other is mechanistically plausible.
The strongest direct mechanistic support comes from PMID 30759446, which found that suppression of KCNQ/M potassium channels in dorsal root ganglion neurons contributes to the development of osteoarthritic pain in an animal model. Since flupirtine pharmacologically opens this same channel, there is a coherent (though indirect) hypothesis that it could counteract this pain-amplifying mechanism. Notably, no study in this evidence pack has tested flupirtine directly in osteoarthritis — the closest direct comparator data exists for a different joint pain condition (gout, see Conclusion).
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30759446 | 2019 | Mechanistic (preclinical) | Pharmacology | Reduced KCNQ2/KCNQ3 expression and M-current density in dorsal root ganglion neurons drive osteoarthritic pain in a rat model, implicating Kv7/M channel opening (flupirtine’s mechanism) as a potential therapeutic strategy |
| 28510996 | 2017 | Systematic Review | Cochrane Database of Systematic Reviews | Reviews tramadol ± paracetamol for cancer pain; general opioid-ladder context, not specific to flupirtine or osteoarthritis |
| 26977921 | 2015 | Review | Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova | Differential diagnosis and treatment review of back pain/spinal osteoarthritis; not drug-specific |
| 25376546 | 2015 | Systematic Review/Meta-analysis | Schmerz (Berlin, Germany) | Compares opioid vs. non-opioid analgesics in chronic non-cancer pain; general background, not flupirtine-specific |
Note: only PMID 30759446 provides a direct mechanistic link to osteoarthritis; the remaining three are background/context references on analgesic classes rather than flupirtine-specific evidence.
Taiwan Market Information
Flupirtine currently holds no marketing authorization in Taiwan (0 registrations on file; market status: Not marketed).
Safety Considerations
Formal safety fields (key warnings, contraindications, drug-drug interactions) are not available in this evidence pack — please refer to the package insert for safety information.
Notable Safety Signal (from mechanistic rationale, not formal safety data): Two lower-ranked predictions in this pack (hepatic porphyria, hepatoportal sclerosis) were flagged as mechanistically contraindicated because flupirtine is hepatically metabolized to reactive quinone-diimine intermediates associated with hepatotoxicity. This is consistent with flupirtine’s known real-world hepatotoxicity risk and should be treated as a priority item for any safety workup, regardless of target indication.
Conclusion and Next Steps
Decision: Hold
Rationale: The osteoarthritis prediction rests on a plausible but indirect mechanistic hypothesis (Kv7 channel opening countering KCNQ suppression seen in osteoarthritic pain models) with no flupirtine-specific clinical or preclinical study in osteoarthritis (Evidence Level L4). The blocking data gap on TFDA label warnings/contraindications (DG001) also prevents completion of the S1 safety screen, and flupirtine’s known hepatotoxicity liability raises the bar for any repurposing decision.
To proceed, the following is needed:
- TFDA/EMA package insert data (warnings, contraindications, hepatotoxicity monitoring requirements) — currently a blocking gap
- Confirmed mechanism-of-action documentation from DrugBank (currently a data gap)
- A flupirtine-specific preclinical or clinical study in osteoarthritis to replace the current indirect mechanistic inference
- Since flupirtine is not marketed in Taiwan, a regulatory/import feasibility assessment before any development track is pursued
Additional note: Among the other candidates in this evidence pack, gout (rank 6, recommendation “Research Question”) has notably more direct evidence — PMID 32062659 directly tested flupirtine (alongside retigabine) in an animal model of gout arthritis pain. This may be a more tractable next research question than osteoarthritis, though it remains preclinical-only.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.